In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Hold rating on Nuwellis (NUWE – Research Report). The company’s shares closed yesterday at $0.26.
Vendetti covers the Healthcare sector, focusing on stocks such as Nuwellis, Lucid Diagnostics, and Biolase. According to TipRanks, Vendetti has an average return of -6.0% and a 32.46% success rate on recommended stocks.
The analyst consensus on Nuwellis is currently a Hold rating.
The company has a one-year high of $3.83 and a one-year low of $0.13. Currently, Nuwellis has an average volume of 5.2M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nuwellis (NUWE) Company Description:
CHF Solutions, Inc. is a medical device company, which engages in the provision of products for the treatment of fluid overload. Its product include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.
Read More on NUWE:
- Nuwellis reports Q1 EPS (60c) vs ($5.76) last year
- Nuwellis receives USPTO notice of patent allowance for CRRT technology
- Nuwellis Announces Closing of $2.7 Million Public Offering
- Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024
- Nuwellis downgraded to Hold from Buy at Maxim
